CGT Future Looks Bright with Syneos Health-Cryoport Alliance

The pharmaceutical, cell, and gene therapy markets are the focus of Cryoport, Inc., a top global provider of innovative temperature-controlled supply chain solutions for the life sciences sector. On January 18, 2023, Cryoport officially announced a new strategic alliance with Syneos Health^®, the sole provider of fully integrated biopharmaceutical solutions designed to hasten client success. The world’s top solution providers Cryoport and Syneos Health^® both have extensive knowledge and experience providing clinical and commercial stage medicines. With the help of the cooperation, which offers the very first seamlessly engaged biopharmaceutical and supply chain solution in the market, cell and gene therapies will advance on a worldwide scale.

The new collaboration combines the complete range of clinical development services provided by Syneos Health^® with IntegriCell^TM, a platform from Cryoport that offers standardized apheresis collection through BioLife Cellular Therapy Services (a division of Takeda), cryopreservation services, risk mitigation services, logistics support, and secondary packaging.

Statements from the C-Suite

Jerrell Shelton, CEO of Cryoport, expresses his delight about joining forces with Syneos Health because both businesses share a similar aim for promoting standardized cell and gene therapies in the field of clinical trials. Shelton is aware of how clinical development, medical affairs, and commercial capabilities are skillfully combined by Syneos Health® to answer contemporary market realities. He is thrilled that Syneos Health^® recognizes the importance of IntegriCell^TM, the first completely standardized apheresis collection and cryoprocessing platform, and the opportunity it presents for the industry. The CEO of Cryoport acknowledges that the work being done by the business with Syneos Health^® highlights the value Cryoport offers to both partners and customers and further solidifies Cryoport’s position as a market leader in the worldwide cell and gene sector.

In a succinct statement, Syneos Health^® COO Michael Brooks highlighted the importance of leveraging the company’s partnership in order to provide insights and seamless integration for critical services for cell and gene trial operations to biopharmaceutical clients. Brooks anticipates that the alliance will help shorten treatment times and improve results by increasing patient access to these revolutionary therapies all around the world.

About Cryoport, Inc.

Global leader in temperature-controlled supply chain solutions for the life sciences sector, Cryoport, Inc. (Nasdaq: CYRX) supports life-saving cell and gene therapies throughout the research, clinical, and commercial spectrum. Cryoport’s global platform offers mission-critical solutions, services, and products to the Biopharma, Animal Health, and Reproductive Medicine markets globally from 38 strategically located locations across the Americas, EMEA (Europe, the Middle East, and Africa), and APAC (Asia Pacific). The largest manufacturer of cryogenic systems in the world and one of the biggest specialist couriers with a focus on life sciences, Cryoport also offers industry-leading supply chain solutions. In total, Cryoport funded 643 clinical trials around the world as of September 30, 2022, 80 of which were in the Phase 3 stage.

Visit www.cryoport.com for further details or go to www.twitter.com/cryoport to follow @cryoport for real-time updates.

About Syneos Health

The only fully integrated biopharmaceutical solutions provider designed specifically to speed up customer success is Syneos Health^® (Nasdaq: SYNH). With a strategic integration of clinical development, medical affairs, and commercial capabilities to suit contemporary market realities, the NASDAQ-listed business leads with a product development approach. With offices in more than 110 countries, Syneos Health^® brings together a brilliant group of experts that have a thorough awareness of market trends as well as patient and physician behavior. In order to accelerate our customers’ delivery of critical therapies to patients, the Syneos stakeholders work together to share insights, employ cutting-edge technology, and implement modern business processes. A diverse, egalitarian, and inclusive culture that values coworkers, clients, patients, communities, and the environment is supported by Syneos Health^®.

Visit syneoshealth.com or subscribe to their podcast to find out how Syneos Health^® is Shortening the distance from lab to life^®.

Engr. Dex Marco Tiu Guibelondo, BS Pharm, RPh, BS CpE

Editor-in-Chief, PharmaFEATURES